Curanex Pharmaceuticals Inc (CURX) stock
Close on Nov 16, 2026Market cap $7.27MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $7.27M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.86
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$12.33M
- EPS, diluted
- -$8.63
- Book value per share
- $1.68
- Diluted shares
- 2M
Trading
- Previous close
- $4.80
- Open
- $4.63
- Day's range
- $4.63 – $4.94
- Volume
- 4,064
- Average volume (20 days)
- 9,201
- 52-week range
- $3.58 – $13.33
- RSI (14 days)
- 40.4
- Volatility (1 year)
- 98.3%
- Relative volume
- 0.24×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | CURX | S&P 500 | Difference | CURX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.3% | -3.1% | +3.4 pts | ||
| 3 months | +6.6% | -4.5% | +11.1 pts | ||
| Year to date | -29.9% | +9.4% | −39.3 pts | ||
| 1 year | -54.3% | +11.3% | −65.6 pts |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Curanex Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- News
- News
- News
About Curanex Pharmaceuticals
Pharmaceutical Preparations
Curanex Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing botanical medicines for patients with inflammatory diseases. The company's lead drug candidate is Phyto-N, a proprietary botanical extract derived from a medicinal plant used in traditional Chinese medicine. Curanex is advancing a development pipeline targeting six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with its primary development focus on ulcerative colitis.
Company profile, executives and historyCuranex Pharmaceuticals stock: common questions
What is Curanex Pharmaceuticals's stock price?
CURX closed at $4.63 on Nov 16, 2026, down 3.44% on the day. Over the past 52 weeks it traded between $3.58 and $13.33.
What is Curanex Pharmaceuticals's market cap?
Curanex Pharmaceuticals was worth $7.27M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is CURX's P/E ratio?
Curanex Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$8.63), so it has no meaningful P/E ratio.
Does Curanex Pharmaceuticals pay a dividend?
No. Curanex Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has CURX stock performed over the past year?
Including dividends, CURX returned -54.3% over the past year, against +11.3% for the S&P 500.
Who are Curanex Pharmaceuticals's competitors?
Companies most similar to Curanex Pharmaceuticals by business, industry and size include ANL, MTRI, EVMN, MENS, EPRX.
See a number that looks wrong?